Venue: Medicon Valley Alliance, Auditorium, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen
Time: 17:00 - 20:00
Welcome to Medicon Valley Alliance R&D Network’s 3rd meeting!
What can R&D learn from orphan drug development:
– The use of AI to find the right patients
– Working closely with stakeholders
Finding the right treatment for the right patient is one major challenge within R&D. The challenges inherent in drug development in rare diseases has enforced stakeholders in this field in pioneering new ways during their R&D.
Medicon Valley Alliance, together with one of their members – Zealand Pharma – also welcomes members of DANISH BIO – DANSK BIOTEK to the MVA R&D Network and their 3rd meeting where we will discuss lessons learned from drug development in rare diseases and how this could be applied to all drug development. Aspects like how to implement AI and how to relate to and interact with the ever-changing stakeholder landscape will be highlighted.
Medicon Valley Alliance R&D Network – an interdisciplinary network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The objective of the network is to strengthen collaboration and knowledge-sharing to stimulate that great science turns into successful innovations for the benefit of patients and society. The network is scheduled to meet twice a year.
The network is free of charge and is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate whether joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically make you able to join the Medicon Valley Alliance R&D Network.